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The patient was successfully extu-
bated. He was transferred to a pneu-
mology ward on day 9 and discharged
on day 15. Antimicrobial treatment
was stopped on day 10.
Most nonhuman strains of V.
metschnikovii  are usually found in
aquatic habitats (e.g., lakes and
marine waters). Human clinical infec-
tions with this bacterium are rare;
however, cases of epidemic diarrhea
caused by V. metschnikovii have been
reported (5,6). Contamination by
water or fish was not always demon-
strated in these cases, but an orofecal
source is possible. In coproculture,
this microorganism is probably not
diagnosed: it was initially identified
as normal aerobic flora because it was
oxidase negative.
The first case of septicemia with V.
metschnikovii was reported in 1981 in
a patient with peritonitis and an
inflamed gallbladder (1). Three other
patients with similar septicemia, all
>70 years of age, were described
(7,8); 2 had polymicrobial results in
blood cultures. V. metschnikovii was
also found in a mucocutaneous site
(wound infection) after saphenectomy
in swab samples of the wound site (9). 
The patient in our study denied
contact with lake or sea water, and he
had not eaten any seafood. He was a
retired carpenter without contact with
domestic or wild animals and did not
recall an episode of diarrhea before
his hospitalization. The source of con-
tamination that caused his acute respi-
ratory failure was not identified. 
Miyake et al. showed that V.
metschnikovii  produces a cytolysin
with hemolytic properties (10). This
finding might explain the invasive
process of this bacterium, which
resulted in pulmonary lesions in a
patient with respiratory deficiency.
As far as we know, this is the first
case of pneumonia caused by V.
metschnikovii.
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Lassa Fever,
Nigeria, 2003 
and 2004
To the Editor: Suspected out-
breaks of Lassa fever have been
reported in the northern part of Edo,
Nigeria, including Ekpoma, Igarra,
and Ibilo, in 2001 and between
November 2003 and March 2004
(1,2). To confirm Lassa fever activity
in this area, serum samples were col-
lected at the Specialist Teaching
Hospital in Irrua (ISTH) from
September 2003 to January 2004.
Approximately 16,000 patients are
seen each year at ISTH, and ≈80% of
them have febrile illness. Serum spec-
imens were taken from patients with
febrile illness (n = 31), healthy con-
tact persons (n = 17), and healthy hos-
pital staff (n = 12). The samples were
analyzed by Lassa virus–specific
reverse-transcriptase polymerase
chain reaction (RT-PCR) at the
University of Lagos. Aliquots of spec-
imens were sent to the Bernhard-
Nocht Institute (BNI in Hamburg,
Germany) for confirmatory PCR
analysis, serologic testing, and virus
isolation. The PCR used at both facil-
ities was based on primers 80F2 and
36E2 that targeted the glycoprotein
precursor (GPC) gene (3), although
the protocols were slightly different.
At BNI, virus RNA was purified by
QIAamp viral RNA kit (Qiagen,
Hilden, Germany), and RT-PCR was
performed with Superscript II
RT/Platinum Taq polymerase 1-step
reagents (Invitrogen, Karlsruhe,
Germany). This PCR assay has a 95%
detection limit of 2,500 copies/mL
(4). At the University of Lagos, virus
RNA purification and RT-PCR were
performed with diatomaceous silica
and Brilliant single-step RT-PCR kit
(Stratagene, Heidelberg, Germany),
respectively. Serologic testing for
Lassa virus–specific immunoglobulin
G (IgG) and IgM was performed by
indirect immunofluorescence assay
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(IFA) by using Vero cells infected
with Lassa virus strain Josiah. Virus
was isolated in the biosafety level 4
laboratory at BNI with Vero cells.
Results of the tests are summarized in
the Table. 
Acute Lassa virus infection, as
shown by a positive PCR result, was
diagnosed at the University of Lagos
in 1 patient. This result was independ-
ently confirmed at BNI, and 2 addi-
tional samples tested positive by PCR.
The PCR signals were weak, which
suggests that discrepancies between
laboratories stem from higher sensi-
tivity of the assay used at BNI.
Presence of a low IgM titer in the
absence of IgG in 2 of the PCR-posi-
tive samples is also consistent with an
acute infection. Two of the Lassa
virus–positive persons (04-02 and 04-
10) had febrile illness that indicated
symptomatic Lassa fever, while 1 (04-
04) had been classified as an asympto-
matic contact at the time of sampling.
Retrospective investigation showed
no evidence of illness in this person
before or after sampling. Sequencing
the diagnostic PCR fragments (300
nucleotides [nt] of GPC gene) from
the 3 patients indicated infections by
closely related strains. The sequence
of patient 04-10 (GenBank accession
no. DQ010031) differed by 4% from
those of patients 04-02 and 04-04,
while the latter sequences were identi-
cal (GenBank accession no.
DQ010030). The facts that patients
04-02 and 04-04 were sisters who
lived in the same house, that their
samples were taken on the same day
(January 28, 2004), and that the
sequences were identical suggest a
common source of infection or an
infection chain. The detection of an
asymptomatic or mild Lassa virus
infection in the contact person agrees
with population-based studies in
Sierra Leone that show only 9%–26%
of all Lassa virus infections are asso-
ciated with fever (5).
In an additional 10 samples, IgM
with or without IgG was detected, pri-
marily in patients with febrile illness.
IgG in the absence of IgM was detect-
ed in 1 contact and 4 healthcare work-
ers. All serologic IFA findings were
confirmed with µ-capture and IgG
enzyme-linked immunosorbent assays
developed at BNI. Virus isolation was
attempted with all samples that tested
positive by PCR or IgM IFA. Lassa
virus was isolated from 1 PCR-posi-
tive serum (04-10). The strain was
designated Nig04-010. To character-
ize Lassa virus circulating in north
Edo, phylogenetic analysis was per-
formed. In addition to the GPC
sequences of the diagnostic PCR frag-
ments, part of the L gene of Nig04-
010 was amplified and sequenced
(780 nt, GenBank accession no.
AY693637). Phylogenetic analysis of
these sequences showed that the virus
circulating around Irrua belongs to
phylogenetic lineage II, which com-
prises Lassa virus strains from the
southeastern part of Nigeria (6). Thus,
genotype and geographic origin of the
viruses characterized here correspond.
These data provide evidence for
Lassa fever activity in north Edo.
Approximately 6% of febrile patients
tested had PCR-confirmed Lassa
fever, which extrapolates to hundreds
of patients with Lassa fever per year,
when one considers the number of
patients with febrile illness seen at
ISTH. As shown here and elsewhere,
PCR is a useful tool to diagnose
Lassa virus infection (3,7), a prereq-
uisite for effective ribavirin treatment
(8). First steps have been made to
establish molecular diagnostics for
Lassa virus at the University of
Lagos. Further efforts are necessary
to improve the laboratory infrastruc-
ture in the country.
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Methicillin-
resistant
Staphylococcus
aureus Skin
Infections
To the Editor: Moran et al. write,
“In areas with a high prevalence of
CA-MRSA [community acquired
methicillin-resistant  Staphylococcus
aureus], empiric treatment for skin
and soft tissue infections (SSTIs) with
β-lactam agents such as cephalexin
may no longer be appropriate. Oral
agents such as clindamycin or
trimethoprim/sulfamethoxazole and
rifampin should be considered in CA-
MRSA” (1). However, some studies
have had different results. Lee et al.
reported that 31 (84%) of 37 Texas
children with CA-MRSA SSTIs
showed clinical improvement after
incision and drainage, even though
they received an “ineffective” antimi-
crobial agent that was not changed
after the susceptibility results became
available (2). These researchers also
reviewed some reports with similar
experience in the United States and
further suggested that incision and
drainage without adjunctive antimi-
crobial therapy were effective in
immunocompetent children for CA-
MRSA SSTIs <5 cm in diameter. 
Several studies on Taiwanese chil-
dren with CA-MRSA SSTIs agree
with the viewpoint of Lee et al. Chen
and colleagues reported that 22 (63%)
of 35 episodes of CA-MRSA superfi-
cial soft tissue infections in children
were cured by nonsusceptible antimi-
crobial therapy, regardless of surgical
intervention (3). In a study by Wang et
al., oxacillin, with or without incision
and drainage, was effective in 16
(89%) of 18 children with CA-MRSA
SSTIs, even in a case with high-level
oxacillin resistance (MIC>8  µg/mL)
(4). Fang et al. also reported that 16
(55%) of 29 children with CA-MRSA
SSTIs were eventually cured with
therapy to which their infections were
not susceptible (5). With these experi-
ences and concerns about the growing
problem of bacterial resistance, we
suggest that incision and drainage,
with or without adjunctive antimicro-
bial therapy, are adequate to treat non-
invasive CA-MRSA SSTIs in
immunocompetent children and that
oxacillin or first-generation cephalo-
sporins are still effective and suffi-
cient under such conditions.
Vancomycin and other agents that are
effective against MRSA isolates
should be reserved for invasive CA-
MRSA infections or for immunocom-
promised patients. Although Moran’s
study was focused on adults, not on
children as these studies were, we
believe these suggestions are also
appropriate when applied to CA-
MRSA SSTIs in adults.
Finally, the antibiogram of CA-
MRSA isolates may vary from coun-
try to country. In Taiwan, CA-MRSA
isolates are also resistant to multiple
antimicrobial agents; 71.4%, 91.4%,
and 41.2% are resistant to clin-
damycin, erythromycin, and chloram-
phenicol, respectively (4). Trimetho-
prim/sulfamethoxazole is more effec-
tive against CA-MRSA isolates than
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